NFKB1 and Miyoshi myopathy: In parallel, Wnt/β-catenin signaling, triggered by stromal cells, drives MM progression and bone disease [14,83,96], while NF-κB activation—observed in over 80% of patients [83]—facilitates immune escape and drug resistance, with ongoing efforts to identify specific upstream drivers like PPFIBP1 [97].